Blockade of NaV1.8 Increases the Susceptibility to Ventricular Arrhythmias During Acute Myocardial Infarction

Baozhen Qi, Shimo Dai, Yu Song, Dongli Shen, Fuhai Li, Lanfang Wei, Chunyu Zhang, Zhenning Nie, Jiaxiong Lin, Lidong Cai, Junbo GeFrontiers in Cardiovascular Medicine 2021 · DOI

Abstract

The sodium channel Na<sub>V</sub>1.8, encoded by the SCN10A gene, has been implicated in cardiac rhythm regulation, yet its precise role and location within the heart remain controversial. This study aimed to determine whether Na<sub>V</sub>1.8 in the intrinsic cardiac nervous system—specifically the ganglionated plexi (GP)—influences ventricular arrhythmogenesis during acute myocardial infarction (AMI). Using a canine model, researchers demonstrated that blocking Na<sub>V</sub>1.8 in the GPs significantly increases the incidence of ventricular fibrillation (VF) and destabilizes ventricular electrophysiology. Molecular analysis confirmed that Na<sub>V</sub>1.8 is expressed in the GPs but not in the ventricular myocardium, suggesting that its cardioprotective effects are mediated through neural modulation rather than direct action on heart muscle.

Introduction

Acute myocardial infarction (AMI) is a leading cause of sudden cardiac death, primarily due to lethal ventricular arrhythmias. The autonomic nervous system, including the intrinsic cardiac nervous system (ICNS), plays a critical role in the electrical stability of the heart during ischemic stress. Recent genetic studies have linked the SCN10A gene to cardiac conduction and arrhythmia risk, but the functional expression of its product, the Na<sub>V</sub>1.8 sodium channel, in the heart is a subject of ongoing debate. While traditionally associated with nociception in the dorsal root ganglia, its presence in the heart's "little brain"—the ganglionated plexi—presents a novel pathway for cardiac regulation.

Methods

The study utilized twenty beagles randomized into two groups: a control group and an A-803467 group (a selective Na<sub>V</sub>1.8 blocker).

Experimental Protocol

  1. GP Blockade: A-803467 (1 μmol/0.5 mL) or DMSO (control) was injected into the four major GPs: the anterior right GP (ARGP), inferior right GP (IRGP), superior left GP (SLGP), and inferior left GP (ILGP).
  2. AMI Induction: Myocardial infarction was induced by occluding the left anterior descending (LAD) coronary artery for one hour.
  3. Electrophysiological Measurements: Ventricular effective refractory period (VERP), action potential duration (APD<sub>90</sub>), and ventricular fibrillation threshold (VFT) were recorded.
  4. Neural Assessment: High-frequency electrical stimulation (HFS) of the ARGP was used to assess the heart rate (HR) response, serving as a proxy for GP activity.
Schematic representation of the heart and the anatomical locations of the targeted ganglionated plexi (GP).

Results

Molecular Localization

Quantitative RT-PCR, Western blot, and immunohistochemistry consistently detected Na<sub>V</sub>1.8 expression within the canine GPs. Conversely, the channel was not validated in the ventricular muscle, indicating that Na<sub>V</sub>1.8's influence on the heart is neurally mediated.

Electrophysiological Impact

Blockade of Na<sub>V</sub>1.8 led to significant electrical instability in the ventricles following AMI:

  • Shortened Refractoriness: Both VERP and APD<sub>90</sub> were significantly shortened in the A-803467 group compared to controls.
  • Reduced Fibrillation Threshold: The VFT was markedly lower in the blocker group, indicating a higher susceptibility to triggered arrhythmias.
Representative ECG and intracardiac electrograms illustrating the ventricular response during the experimental protocol.

Arrhythmia Incidence

The most striking finding was the clinical outcome: 90% of the subjects in the A-803467 group developed ventricular fibrillation during the one-hour occlusion period, compared to only 30% in the control group (p < 0.05). Furthermore, the blocker suppressed the HR slowing typically induced by HFS of the ARGP, confirming that Na<sub>V</sub>1.8 inhibition reduces GP activity.

Discussion

This study provides the first evidence that Na<sub>V</sub>1.8 in the ganglionated plexi serves as a critical regulator of ventricular stability during the early stages of a heart attack. The finding that Na<sub>V</sub>1.8 is present in the ICNS but absent in the myocardium clarifies the mechanism behind SCN10A-associated arrhythmia risk.

Interestingly, while GP hyperactivity is often linked to arrhythmias, this study suggests that a baseline level of GP activity—mediated by Na<sub>V</sub>1.8—is necessary to maintain ventricular refractoriness and protect against fibrillation during ischemia. The "numbing" of these neural clusters via Na<sub>V</sub>1.8 blockade appears to remove a protective autonomic brake, leading to rapid electrical recovery and chaotic re-entry.

Conclusion

Blockade of Na<sub>V</sub>1.8 in the cardiac ganglionated plexi significantly increases the risk of fatal ventricular arrhythmias during acute myocardial infarction. These findings highlight the importance of the intrinsic cardiac nervous system in post-infarction stability and suggest that Na<sub>V</sub>1.8 may be a viable therapeutic target. Future research into Na<sub>V</sub>1.8 activators could potentially offer a new strategy for preventing sudden cardiac death in AMI patients.

Summary updated

Abstract

<i>SCN10A</i>/Na<sub>V</sub>1.8 may be associated with a lower risk of ventricular fibrillation in the setting of acute myocardial infarction (AMI), but if and by which mechanism Na<sub>V</sub>1.8 impacts on ventricular electrophysiology is still a matter of debate. The purpose of this study was to elucidate the contribution of Na<sub>V</sub>1.8 in ganglionated plexi (GP) to ventricular arrhythmias in the AMI model. Twenty beagles were randomized to either the A-803467 group (<i>n</i> = 10) or the control group (<i>n</i> = 10). Na<sub>V</sub>1.8 blocker (A-803467, 1 μmol/0.5 mL per GP) or DMSO (0.5 mL per GP) was injected into four major GPs. Ventricular effective refractory period, APD<sub>90</sub>, ventricular fibrillation threshold, and the incidence of ventricular arrhythmias were measured 1 h after left anterior descending coronary artery occlusion. A-803467 significantly shortened ventricular effective refractory period, APD<sub>90</sub>, and ventricular fibrillation threshold compared to control. In the A-803467 group, the incidence of ventricular arrhythmias was significantly higher compared to control. A-803467 suppressed the slowing of heart rate response to high-frequency electrical stimulation of the anterior right GP, suggesting that A-803467 could inhibit GP activity. <i>SCN10A</i>/Na<sub>V</sub>1.8 was readily detected in GPs, but was not validated in ventricles by quantitative RT-PCR, western blot and immunohistochemistry. While <i>SCN10A</i>/Na<sub>V</sub>1.8 is detectible in canine GPs but not in ventricles, blockade of Na<sub>V</sub>1.8 in GP increases the incidence of ventricular arrhythmias in AMI hearts. Our study shows for the first time an influence of <i>SCN10A</i>/Na<sub>V</sub>1.8 on the regulation of ventricular arrhythmogenesis via modulating GP activity in the AMI model.
BibTeX
@inproceedings{qi2021blockade,
  author = {Baozhen Qi and Shimo Dai and Yu Song and Dongli Shen and Fuhai Li and Lanfang Wei and Chunyu Zhang and Zhenning Nie and Jiaxiong Lin and Lidong Cai and Junbo Ge},
  title = {{Blockade of NaV1.8 Increases the Susceptibility to Ventricular Arrhythmias During Acute Myocardial Infarction}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.708279},
}
Figure